MedPath

OCT and Early Cognitive Impairment in Multiple Sclerosis

Completed
Conditions
Multiple Sclerosis
Registration Number
NCT04153773
Lead Sponsor
Mansoura University Hospital
Brief Summary

The aim of this study is to investigate the relationship between cognitive impairment and retinal nerve fiber layer \& ganglion cell inner plexiform layer in MS.

Detailed Description

Cross-sectional study design, including 60 patients and 30 healthy controls. Subjects were investigated clinically, underwent retinal optical coherence tomography (OCT) and comprehensive cognitive assessments. The correlation between these modalities was evaluated by Spearman correlation.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria
  • 60 MS patients diagnosed according to the revised McDonald criteria 2010 were included
  • 30 healthy subjects with age and sex match control group.
Exclusion Criteria
  • Medical disorder other than MS that may grossly affect cognitive functions
  • Pregnancy,
  • Previous neurological or neuropsychiatric disorders,
  • Alcohol or drug abuse,
  • MRI findings which could not be attributed to MS.
  • Severe visual disorders (> ± 6.0 dpt.)
  • History of ocular surgery, glaucoma or diabetes.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Optical coherence tomography24-48 hours

OCT imaging was performed by spectral domain-optical coherence tomography to assess the retinal thickness.

Secondary Outcome Measures
NameTimeMethod
Cognitive assessment24-48 hours

Neurocognitive functions were evaluated using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

Expanded Disability Status Scale (EDSS)24 hours

The EDSS score ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.

Trial Locations

Locations (1)

Mansoura University Hospital

🇪🇬

Mansoura, Dakahlia, Egypt

Mansoura University Hospital
🇪🇬Mansoura, Dakahlia, Egypt

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.